Isolated nucleic acid molecule, recombinant virus or use thereof

By designing nucleic acid molecules and recombinant viruses encoding VEGFR analogs, packaging them into AAV viruses and injecting them into the patient's eyes, solving the problems of high recurrence rates and high injection frequency of existing wAMD treatment methods, and achieving long-term VEGF inhibition and high efficiency Abnormal neovascular growth inhibition reduces the risk of intraocular inflammation.

CN117535299BActive Publication Date: 2024-12-06BEIJING BIOLOGICAL PROD INST CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311410653.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-27
Publication Date
2024-12-06
Estimated Expiration
2043-10-27

AI Technical Summary

Technical Problem

Existing wet age-related macular degeneration (wAMD) treatments such as photodynamic therapy and antibody/recombinant proteins lead to low patient burden and compliance due to high recurrence rates, high injection frequency and potential intraocular inflammation, and The drug has a short half-life and is difficult to be effective in the long term.

Method used

An improved nucleic acid molecule and recombinant virus were designed to encode VEGFR analog, packaged into AAV virus, injected into the patient's eyes, express drug structural proteins and secreted out of the cell, and compete to bind VEGF to inhibit cell proliferation signals, achieving Effects of inhibiting abnormal neovascular growth.

Benefits of technology

Long-term VEGF inhibition was achieved, with high expression of target protein, strong affinity, and maintained drug efficacy for several years and even lifelong, reducing the frequency of treatment and the risk of intraocular inflammation, and improving patient compliance and treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117535299B_ABST
    Figure CN117535299B_ABST
Patent Text Reader

Abstract

The present invention relates to an isolated nucleic acid molecule, a recombinant virus or a use thereof. Specifically, the present invention relates to an isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleotide sequence shown in SEQ ID NO: 3. Gene therapy using the nucleic acid molecule or recombinant virus of the present invention can provide prolonged or sustained therapeutic efficacy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene therapy. Specifically, the present invention relates to an isolated nucleic acid molecule, a recombinant virus or an application thereof. More specifically, the nucleic acid molecule and the recombinant virus of the present invention can be used to treat or prevent eye diseases associated with VEGF, in particular, wet age-related macular degeneration. Background Art

[0002] Age-related macular degeneration (AMD) is a progressive, chronic disease of the central retina that primarily affects the macular region of the retina. It is common in people over 60 years old and is one of the leading causes of irreversible blindness in the elderly (1). AMD can be divided into two types: dry and wet. The dry type is a non-exudative type, characterized by the formation of drusen and proliferation or loss of the retinal pigment epithelium. The wet type is a neovascular type, characterized by choroidal neovascularization leading to bleeding and exudation (2). Blood vessels can transport nutrients to tissues and organs and remove metabolic products. Therefore, the development of new blood vessel supply or angiogenesis plays a homeostatic role in many important physiological processes. However, uncontrolled blood vessel growth can promote the occurrence and development of a variety of diseases, mainly including tumors and intraocular vascular diseases (2). Existing research results show that many eye diseases involve abnormal vascular development, among which abnormal proliferation of retinal and choroidal neovascularization is the main cause of vision loss in eye diseases. Wet age-related macular degeneration (wet-AMD) is mainly characterized by abnormal growth of new blood vessels under the retina in the macula, called choroidal neovascularization (CNV), which leads to local edema or hemorrhage in the macular area, causing bulge in the macular area and localized pigment epithelial detachment, eventually leading to scar formation, damaging retinal photoreceptor cells and causing vision loss.

[0003] Vascular endothelial growth factor (VEGF) is a growth factor with important pro-angiogenic activity. It can promote mitosis and anti-apoptosis of endothelial cells, increase vascular permeability, promote cell migration, etc., and can regulate physiological and pathological angiogenesis processes (3). VEGF is the main mediator of abnormal blood vessel growth from the choroid to the neural retina in various eye diseases, and plays an important role in the formation of choroidal neovascularization in wAMD patients (4). Inhibiting the activity of vascular endothelial growth factor (VEGF) is the standard treatment for neovascular eye diseases.

[0004] Currently, the more mature treatment options include not only surgical treatments such as photodynamic therapy (PDT) and laser photocoagulation, but also antibody and recombinant protein drug treatments.

[0005] Photodynamic therapy is a type of photochemotherapy, which uses laser to irradiate biological tissues stained with chemical substances, producing a photochemical effect to damage the target tissues and thus achieve the treatment purpose. This method of treating wAMD involves the use of low-intensity laser combined with photosensitizers to surgically remove abnormal new blood vessels growing in the macula under the retina, and scars caused by macular edema or hemorrhage caused by localized pigment epithelial detachment and macular bulges (7).

[0006] However, for photodynamic therapy, some patients may experience recurrence of lesions after a single treatment and may need repeated treatment. Some patients may even need treatment more than three times a year. Many studies have confirmed that photosensitizers can be retained in large quantities in the vascular tissue of tumors, and the endothelial cell membranes of blood vessels contaminated with photosensitizers are damaged, causing thrombosis and occlusion of new blood vessels in the blood vessels (7).

[0007] Antibody and recombinant protein drug treatments block the binding of VEGF to VEGFR on the surface of vascular endothelial cells, inhibiting the transmission of cell signals downstream after binding. Targeted treatment is performed using monoclonal antibodies or recombinant protein drugs against VEGF.

[0008] VEGF is vascular endothelial growth factor, which is the main mediator of abnormal blood vessel growth from the choroid to the neural retina in various eye diseases such as wAMD. It can bind to VEGFR on the cell surface and activate the downstream pathway of angiogenesis. The use of competitive protein drugs to inhibit the activity of VEGF has become an important means of treating wAMD. Such drugs that have been used in clinical practice include: aflibercept, ranibizumab, bevacizumab, and conbercept (5). Among them, ranibizumab and bevacizumab are monoclonal antibodies to VEGF, and aflibercept and conbercept are recombinant proteins with similar structures to VEGFR, which are composed of the extracellular domains of VEGF receptors 1 and 2 and the Fc part of IgG (8). Both of them specifically bind to free VEGF, hinder VEGF from binding to VEGFR on the cell surface, and inhibit VEGFR from transmitting pro-angiogenic signals to the cell interior by reducing the binding efficiency (9). Studies have confirmed that the use of antibodies and recombinant protein drugs has reduced the blindness rate of ophthalmic diseases caused by abnormal VEGF expression.

[0009] There are two main design directions for protein drugs for wAMD. The first is a monoclonal antibody to VEGF, which can specifically bind to VEGF molecules. The second is a protein similar to VEGF receptor, whose main design structure is a combination of the VEGF-binding domains of VEGFR1 and VEGFR2.

[0010] However, due to the nature of free proteins, antibody drugs and recombinant protein drugs have a short half-life in the body, requiring patients to undergo intravitreal injections every 1-2 months (for example, patients with age-related macular degeneration require intravitreal injections at an average frequency of one injection every 1-3 months). This undoubtedly increases the burden on both patients and medical staff, and also brings the risk of injection-induced intraocular inflammation, retinal detachment, and eye hemorrhage (6). In addition, medication must be taken for a long time. If the patient does not take medication for 2 years after diagnosis, the chance of developing blindness will greatly increase. Multiple intravitreal injections in both eyes over a year and all year round impose a relatively large burden on both patients' compliance and doctors.

[0011] In addition to the above two methods, gene therapy is also being studied and developed. AAV has unique properties (such as non-pathogenicity) and has persistent transgene expression, which makes it an extremely attractive therapeutic gene delivery vector.

[0012] The principle of AAV viral vector gene therapy is to insert the drug structure gene with therapeutic effect into the genome of the viral vector. The drug structure gene is released into the patient's body with AAV virus infection and transcribes to express the drug structure protein. Since the immunogenicity of AAV virus is low, it will not cause disease to the host and can be protected from the attack of the host immune system. The drug structure gene carried in the viral vector can efficiently express the drug protein in the animal body for a long time, thus achieving the purpose of long-term effectiveness with one injection.

[0013] For example, the drug zolgensma developed by Novartis for the treatment of spinal muscular atrophy (SMA) uses AAV virus as a delivery vector to carry and express the SMN gene in the body to supplement the related proteins lacking in the body. A single injection currently has 7.5 years of effective data. Compared with Biogen's protein drug nusinersen sodium injection (Spinraza), which requires multiple injections a year, it has more advantages.

[0014] The drug structure gene carried and expressed by the gene therapy drug for wAMD is the genetic basis of the expressed drug protein and the core content of the efficacy of the gene therapy drug. It is necessary to further improve the drug structure gene. Summary of the invention

[0015] The purpose of the present invention is to provide an improved drug structure gene, and package it into the capsid of the AAV virus, and its expression product is a VEGFR analog, which can inhibit the growth of abnormal new blood vessels in the retina. When taking the medicine, as the AAV virus is injected into the patient's eye, the AAV can express the drug structure protein after infecting the vascular cells, and the drug structure protein is secreted outside the cell under the action of the signal peptide. This drug structure protein can compete with the VEGFR expressed on the surface of vascular endothelial cells to bind to free VEGF, thereby inhibiting the binding of free VEGF to the VEGFR on the cell surface, and then inhibiting the conduction of cell proliferation signals, thereby achieving the effect of inhibiting cell proliferation.

[0016] In one aspect, the present invention provides an isolated nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:3.

[0017] In one embodiment, the nucleic acid molecule further comprises a signal peptide number nucleotide sequence as shown in SEQ ID NO:9.

[0018] In one embodiment, the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:1.

[0019] In one embodiment, the nucleic acid molecule encodes an amino acid sequence comprising SEQ ID NO:5 or 7.

[0020] In one aspect, the present invention provides an isolated nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:4.

[0021] In one embodiment, the nucleic acid molecule further comprises a signal peptide number nucleotide sequence shown in SEQ ID NO:10.

[0022] In one embodiment, the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:2.

[0023] In one embodiment, the nucleic acid molecule encodes an amino acid sequence comprising SEQ ID NO: 6 or 8.

[0024] In another aspect, the present invention provides a recombinant virus, the recombinant virus comprising any of the nucleic acid molecules described above, and further comprising a combination of regulatory elements in the following polynucleotide expression cassettes:

[0025] (1) Inverted terminal repeat sequence ITR1 of AAV2 virus

[0026] (2) CMV promoter: It is used to initiate transcription and expression of gene sequences

[0027] (3) CMV enhancer: It acts as a cis-acting element

[0028] (4) Kozak sequence: The ribosome can recognize this sequence on the mRNA and use it as the translation start site

[0029] (5) VEGFR1 signal peptide: It is used to guide the transfer of newly synthesized proteins to the secretory pathway:

[0030] (6) BGH PloyA sequence: a key regulator of gene expression in the cytoplasm

[0031] In one embodiment, the virus is an adeno-associated virus (AAV), for example, the AAV virus is selected from any of the following serotypes: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 or AAV11.

[0032] In one embodiment, the virus is AAV8.

[0033] In another aspect, the present invention provides use of the above nucleic acid molecule or the above recombinant virus in the preparation of a drug for treating or preventing an eye disease associated with VEGF.

[0034] In one embodiment, the VEGF-associated ocular disease is an ocular disease of intraocular neovascularization.

[0035] In one embodiment, the VEGF-related eye disease is age-related macular degeneration, preferably wet age-related macular degeneration.

[0036] In another aspect, the present invention provides a method for treating an eye disease associated with VEGF, the method comprising administering a therapeutically effective amount of the above nucleic acid molecule or the above recombinant virus to a subject, wherein the administration comprises intravitreal injection.

[0037] Beneficial Effects

[0038] The present invention can provide a long-acting drug for eye diseases related to VEGF. After being injected into the human body, the target protein expression level is higher and the affinity is stronger, and the drug efficacy can be maintained for several years or even for life. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 A graph showing the ability of SPR method to detect the binding between drug structural protein and effector protein.

[0040] Figure 2 Western Blot image showing PCNA expression in 293 cells infected with AAV virus carrying drug structure.

[0041] Figure 3 A graph showing the results of a CCK8 experiment in HUVEC cells infected with AAV virus carrying the drug structure.

[0042] Figure 4 A graph showing in vivo efficacy results. DETAILED DESCRIPTION

[0043] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical solution of the present invention is now described in detail below, but it should not be construed as limiting the applicable scope of the present invention.

[0044] The present invention generally relates to two nucleic acid sequences and AAV viruses for gene therapy of wAMD, the two nucleic acid sequences are called DS032 and DS035, encoding VEGFR analogs, and the two AAV viruses are AAV-AMDVR032 and AAV-AMDVR035.

[0045] In this study, compared with the protein drug aflibercept, the drug structure sequence was upgraded. The D1 region of VEGFR1 was added to the DS032 sequence to increase the expression of the target protein, and the D4 region of VEGFR2 was added to form a more stable dimer structure. The D1 region of VEGFR1 was added to the DS035 sequence compared to aflibercept, and the D3 region of VEGRF2 of aflibercept was changed to the D3 region of VEGFR1, so that the region that binds to VEGF is consistent with the natural protein, increasing the stability and biological activity of the effector protein. The drug structure sequence was set in the AAV virus expression cassette, which improved the drug expression beam, increased the stability and timeliness of the drug, and thus improved the compliance and expected effect of the drug.

[0046] The complete DNA sequences of DS032 and DS035 are shown below as SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

[0047]

[0048]

[0049] Among them, bold indicates the signal peptide encoding nucleic acid sequence

[0050] The DNA sequences of DS032 and DS0355 without the signal peptide encoding nucleic acid sequence are shown in the following SEQ ID NO: 3 and SEQ ID NO: 4.

[0051]

[0052]

[0053] The complete amino acid sequences of DS032 and DS035 are shown below in SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0054]

[0055] The bold indicates the signal peptide sequence

[0056] The amino acid sequences of DS032 and DS035 without the signal peptide are shown in the following SEQ ID NO: 7 and SEQ ID NO: 8.

[0057]

[0058] In the complete DNA sequences of DS032 and DSP035, the signal peptide encoding nucleic acid sequences are shown in the following SEQ ID NO: 9 and SEQ ID NO: 10, respectively.

[0059]

[0060] In the complete amino acid sequences of DS032 and DS035, the signal peptide sequences are shown in the following SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

[0061]

[0062] The present invention provides an isolated nucleic acid molecule, which comprises a nucleotide sequence as shown in any one of SEQ ID NOs: 1-4, or encodes an amino acid sequence as shown in any one of SEQ ID NOs: 5-8.

[0063] The nucleic acid molecule can be used as a VEGFR analog coding sequence to encode a drug structure for gene therapy of wAMD. The drug structure is packaged into a vector virus, especially an AAV virus. When the drug is used, as the AAV virus is injected into the patient's eye, the AAV infects the vascular cells and can express the drug structure protein, which is secreted outside the cells under the action of the signal peptide. The drug structure protein can competitively bind to free VEGF with VEGFR expressed on the surface of vascular endothelial cells, thereby inhibiting the binding of free VEGF to VEGFR on the cell surface, and then inhibiting the conduction of cell proliferation signals, thereby achieving the effect of inhibiting cell proliferation.

[0064] AAV serotypes include AAV1, AAV2, AAV2.5, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, AAV-DJ, and any hybrid or chimeric AAV thereof. In some embodiments, the serotype used is based on the tropism of the virus, or the infectivity to the target cell of interest. In one embodiment, the virus is AAV8.

[0065] In some embodiments, AAV is used to deliver nucleic acid sequences to the eye or retinal cells of a subject by intravitreal or subretinal injection. In some embodiments, AAV is used to deliver nucleic acid sequences to retinal cells of a subject.

[0066] One advantage of gene therapy over protein injections is that gene therapy provides extended or sustained release of therapeutic agents (e.g., DS032 and DS035 proteins of the present invention), and in some embodiments, multiple or repeated injections are not required. This extended or sustained release is caused by the delivery of nucleic acid sequences encoding DS032 and DS035 proteins, which are expressed in vivo to provide a therapeutic effect. In some embodiments, expression of the protein by the heterologous nucleic acid delivered to the retinal cells can last for at least 1 year, more than 1 year, at least 2, 3, 4, 5, 10 years or more, or even for a lifetime.

[0067] In some embodiments, AAV can comprise a capsid variant protein that increases its infectivity to target cells or target tissues (e.g., retinal cells) in the eye, allowing for more efficient delivery of nucleic acid sequences encoding therapeutic transgenes to target cells or target tissues, where the therapeutic transgenes can be expressed for a period of time (e.g., at least 1, 1.5, 2, 3, 4, 5, 10 years or more). Gene therapy as disclosed herein can target specific tissues or cell types of interest (e.g., photoreceptor cells), which can help minimize off-target effects, or provide more targeted in vivo delivery of therapeutic drug structures.

[0068] Prolonged or sustained delivery of DS032 and DS035 gene sequences in vivo via gene therapy allows for administration of drugs in fewer doses over a period of time compared to currently used standard therapies (e.g., protein injections or non-gene therapy-based treatments).

[0069] In another aspect, the present invention provides the use of the above-mentioned nucleic acid molecules or the above-mentioned recombinant viruses in the preparation of a medicament for treating or preventing an eye disease associated with VEGF. In some embodiments, the disease is selected from: ocular neovascular diseases, including age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy and diabetic retinal edema and any combination thereof. In one embodiment, the eye disease associated with VEGF is age-related macular degeneration, preferably wet age-related macular degeneration.

[0070] In one embodiment, the medicine includes a pharmaceutically acceptable excipient in addition to comprising the above-mentioned nucleic acid molecules or the above-mentioned recombinant virus. In some cases, the excipient includes a surfactant or a stabilizer. In some cases, the surfactant is selected from polysorbate, sodium lauryl sulfate, sodium lauryl sulfate, lauryl dimethyl amine oxide, polyethoxylated alcohol, polyoxyethylene sorbitan, octoxynol, Brij, pluronic and polyoxyethylene castor oil. In some cases, the pharmaceutically acceptable excipient includes phenol, mannitol, sorbitol or sodium chloride.

[0071] Example

[0072] The technical solution provided by the present invention is generally described as follows.

[0073] 1. Design the main drug structures of two wAMD gene therapy drugs.

[0074] 2. The drug structure gene sequence was codon optimized and constructed into the plasmid pGOI-AMDVR expression cassette for AAV virus packaging.

[0075] 3. Co-transfect HEK293 cells with plasmid pGOI-AMDVR, plasmid pHelper and plasmid pAAV8-CapRep to package virus AAV-AMDVR.

[0076] 4. The ELISA method was used to detect the expression level of drug structure protein after the AAV virus carrying the drug structure infected human umbilical vein endothelial cells.

[0077] 5. Use surface plasmon resonance (SPR) technology to detect the affinity between drug structural protein and VEGF.

[0078] 6. Use western blot method to detect the regulatory changes of genes related to human umbilical vein endothelial cell proliferation after AAV virus infection expressing drug structure at the protein level.

[0079] 7. Use the CCK8 method to identify at the cellular level the changes in the proliferation ability of human umbilical vein endothelial cells after infection with AAV virus expressing the drug structural protein.

[0080] Each step is described in detail below.

[0081] Example 1. Design of the main drug structure of wAMD gene therapy drugs.

[0082] In this study, two drug structure sequences for wAMD gene therapy drugs were designed, drug structure 1 (DS032) and drug structure 2 (DS035). The main design concept is to use the different domains of VEGFR1 and VEGFR2 proteins for multiple combinations, and at the same time combine with the Fc segment of IgG.

[0083] Example 2. Codon optimization of drug structure gene sequence and construction into plasmid pGOI-AMDVR for AAV virus packaging. In order to increase the expression capacity of drug structure protein gene in future target cells, codon optimization of gene sequence was performed.

[0084] Example 3. Plasmid pGOI-AMDVR was co-transfected with plasmid pHelper and plasmid pAAV8-CapRep into HEK293 cells to package virus AAV-AMDVR.

[0085] 1) Cell culture. Add 3.5×10 6 The culture medium volume is 30 mL. The cells are cultured until the cell density is 90% full. The original cell culture medium is discarded and replaced with 5% FBSDMEM. The cells are placed in a 37°C carbon dioxide incubator and cultured for 1 hour before cell transfection.

[0086] 2) Preparation of PEI plasmid complex: Add 10ug AAV-Helper, 10ug AAV-Rep2Cap8, and 10ug pGOI-AMDVR to 3mL opti-DMEM, mix thoroughly, then add 90uL PEI, shake and mix, and let stand at room temperature for 15 minutes.

[0087] 3) Cell transfection: Add all the PEI plasmid complexes to the cell culture flask that has been incubated for 1 hour after changing the medium, gently mix the cell culture medium, and continue culturing in a 5% CO2, 37°C incubator.

[0088] 4) Change the transfection medium. 24 hours after transfection, change the cell medium, discard the original transfection medium, add 30mL of DMEM containing 4uM L-glutamine and 4.5g / L glucose, and continue culturing in a 37℃ carbon dioxide incubator.

[0089] 5) Harvest the virus harvest solution. After the transfection and medium change, the T75 culture flask cells are cultured for 72 hours before the virus harvest solution is harvested. The harvest is the cell culture medium supernatant and cell pellet. The virus harvest solution is placed in liquid nitrogen and a 37°C water bath and repeatedly frozen and thawed three times. Centrifuge at 900 rpm for 10 minutes at a centrifugation temperature of 4°C, and the supernatant is aspirated for genome titer detection.

[0090] 6) AAV purification: AAV virus was purified using an AAV virus purification kit (ViraTrap Adeno-associated Virus Large-Scale Purification Kit (All Serotypes) (Manufacturer: Biomiga; Catalog Number: BW-V1369)) according to the specific requirements of the instruction manual.

[0091] Example 4. Detection of the expression level of drug structural protein by ELISA method.

[0092] (1) Principle: AAV-AMDVR virus-infected susceptible cells will overexpress drug structural proteins in the cells, and secrete them outside the cells under the action of signal peptides. VEGF protein is used to coat the plate, and different concentrations of infected cell protein lysates are co-incubated with it. The free drug structural proteins in the cell protein lysates are quantitatively detected by ELISA experiments, and the affinity and total amount of expression of the target drug structural proteins with the ligand are analyzed, which is then used as an in vitro efficacy indicator.

[0093] (2) Steps: Coat the ELISA plate with 500 ng / mL VEGF protein, add 100 μL to each well, and incubate overnight at 4°C; wash the plate 4 times with PBST (PBS containing 0.1% Tween), and block with PBST containing 5% BSA at 37°C for 2 hours; after washing the plate 4 times with PBST, add 250 ng / mL-1.953 ng / mL standard in a gradient manner, and draw a standard curve. Add gradient diluted cell protein lysate (original / 2-fold / 4-fold / 8-fold / 16-fold dilution), with two replicate wells for each dilution gradient; add gradient diluted aflibercept (0.05 pM-400 pM) as a positive control, with two replicate wells for each dilution gradient. After incubating at 37°C for 2 hours, wash the plate 4 times with PBST. Add rabbit anti-human enzyme-labeled secondary antibody, dilute 1:30000, incubate at 37°C for 1.5 hours; wash 4 times with PBST, add 50ul of colorimetric solution A and 50ul of colorimetric solution B, add 50uL of stop solution, incubate for 15 minutes, and read the absorbance at 450nm and 630nm.

[0094] (3) Results: AAV viruses carrying two drug structural protein genes can express drug structural proteins after infecting effector cells. The expression levels and expression results are shown in Table 1.

[0095] Table 1. Protein expression in effector cells after infection by AAV virus carrying the structural protein genes of the two drugs

[0096]

[0097] Example 5. Detecting the affinity between drug structural protein and VEGF using surface plasmon resonance (SPR) technology.

[0098] (1) Principle: Biacore T200 is a high-throughput molecular-level interaction analysis system based on surface plasmon resonance (SPR) technology. The expressed and purified VEGF molecule is fixed on the biosensor chip by amino coupling, and the drug structural protein to be tested flows over the chip surface at a certain concentration. If there is an interaction between the two, the refractive index of the chip surface changes, resulting in a change in the resonance angle. By detecting the change in the resonance angle in real time, the kinetics and affinity information of the molecular interaction between the drug structural protein and VEGF are collected to determine the affinity of the two.

[0099] (2) Steps: Use EDC / NHS in the amino coupling kit to activate the chip, dilute VEGF with sodium acetate and fix it on the chip, and block it with ethanolamine. Prepare the drug structure protein and prepare analyte solutions with concentrations of 85nM, 8.5nM, and 0.85nM respectively. The drug structure protein solution flows through the chip, and the response value of the channel is used to determine whether there is non-specific binding between the analyte and the chip surface. Aflibercept solution is used as a positive control.

[0100] (3) Results: SPR detection revealed that both drug structural proteins DS032 and DS035 can bind to the target effector protein. Figure 1 .

[0101] Example 6. The regulatory changes of genes related to proliferation of human umbilical vein endothelial cells after infection with AAV virus expressing the drug structure were detected at the protein level using the western blot method.

[0102] (1) Principle: HUVEC cells are human umbilical vein endothelial cells, which are model cells of vascular endothelium. They can constitutively express VEGF factor and VEGFR on the cell surface. When the AAV-AMDVR virus carrying the drug structure gene infects HUVEC cells, the drug structure protein AMDVR is expressed in the cells and secreted into the cell culture supernatant medium under the action of the signal peptide. The drug structure protein AMDVR can competitively bind to the free VEGF factor expressed outside the HUVEC cells, inhibit the binding of VEGF-VEGFR and the transduction of signals, and lead to the downregulation of the expression of marker proteins necessary for cell proliferation. The expression level of the marker protein is detected by western blot to determine whether the expression of the secondary marker protein is downregulated, and then to determine the inhibitory effect of the drug structure protein expressed by the drug structure gene delivered by AAV on the proliferation of vascular endothelial cells.

[0103] (2) Steps: HUVEC cells were cultured in a 6-well plate until 90% confluence, the cells were washed three times with PBS, and fresh culture medium was added. AAV-AMDVR1-6 viruses were diluted in serum-free culture medium at 5×10 4 vg / cell, 5×10 5 vg / cell, 5×10 6 vg / cell gradient infection of HUVEC cells, each dilution set 4 replicates, placed in a cell culture incubator for 4h, then replaced with fresh culture medium, 72h after infection, cells were collected by cell scraper. Add 60uL cell lysis solution (1mM PMSF) to the collected cells, lyse on ice for 30 minutes, then centrifuge at 4℃, 13000rpm for 10 minutes, transfer the supernatant to a new 1.5mL EP tube. Add 15uL 5×SDS-PAGE loading buffer to it and boil it in boiling water for 10 minutes. Perform SDS-PAGE electrophoresis on the sample. After the electrophoresis is completed, remove the gel block, rinse the lower gel with double distilled water, and remove the residual electrophoresis solution. The protein bands on the gel block were transferred to the PVDF membrane. After the transfer, the PVDF membrane was rinsed with double distilled water to remove the residual electrotransfer solution. The PVDF membrane was transferred to a 5% skim milk solution and blocked for 2 hours at room temperature on a shaker. The monoclonal antibodies of Cyclin E1, BCL2, PCNA and GAPDH were incubated separately and incubated overnight at 4°C on a shaker. The PVDF membrane was washed 5 times with 5% PBST for 5 minutes each time, and then incubated with the corresponding horseradish peroxidase-labeled secondary antibody at room temperature for 1 hour. After the incubation, the PVDF membrane was washed 5 times with 5% PBST for 5 minutes each time. Enhanced chemiluminescence (ECL) colorimetric solution was prepared and added to the PVDF membrane. The gray value of the protein band was calculated by scanning the membrane, and the changes in protein expression were determined by combining the internal reference.

[0104] (3) Results: Western Blot results showed that AAV virus carrying drug structure infected vascular endothelial cells and had an inhibitory effect on cell proliferation effector proteins; the inhibitory effect of AAV virus carrying drug structure on effector proteins had a dose-effect relationship; different drug structures had different inhibitory effects on effector proteins. Figure 2 .

[0105] Example 7. Using the CCK8 method to identify changes in the proliferation ability of human umbilical vein endothelial cells after infection with AAV virus expressing drug structural proteins.

[0106] (1) Principle: Cell Counting Kit-8 (CCK-8 for short) is a WST-8-based reagent widely used for detecting cell proliferation and cytotoxicity. WST-8, chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonate)-2H-tetrazolyl monosodium salt, is a compound similar to MTT. In the presence of electron carrier 1-methoxy-5-methylphenazinium dimethyl sulfate (1-Methoxy PMS), it is reduced by mitochondrial dehydrogenase to a highly water-soluble orange-yellow formazan product (formazan). The more and faster the cell proliferation, the darker the color; the greater the cytotoxicity, the lighter the color. For the same cells, the depth of the color is proportional to the number of living cells. Therefore, this characteristic can be used to directly analyze cell proliferation and toxicity. The amount of formazan in HUVEC cells infected with AAV-AMDVR was detected by CCK-8 kit combined with microplate reader to measure the effect of gene drugs such as rAAV-FLT1 on HUVEC cell proliferation.

[0107] (2) Step: Add 100uL of HUVEC cell suspension (about 2000 cells) to a 96-well plate and culture overnight in a 37°C, 5% CO2 cell culture incubator. Add 5×10 4 vg / cell, 5×10 5 vg / cell, 5×10 6 vg / cell AAV-AMDVR1-6 virus. At 24, 48, and 72 hours after virus infection, 10uCCK-8 solution was added to each well, and the cells were cultured in a 37°C, 5% CO2 cell culture incubator for 2-4 hours. The absorbance of the samples at 450nm was detected using an ELISA reader.

[0108] (3) Results: The results of the CCK8 experiment showed that AAV viruses carrying different drug structural genes had an inhibitory effect on the proliferation of effector cells HUVEC (venous endothelial cells), and there was a certain dose-effect relationship. For specific results, see Figure 3 .

[0109] Example 8. Mouse modeling and in vivo expression and efficacy studies

[0110] (1) Principle: The mouse choroidal neovascularization (CNV) model was induced by laser photocoagulation to preliminarily investigate the possible effect of a single intravitreal injection of the test article on mouse CNV.

[0111] (2) Procedure: 32 C57BL / 6J mice (16 mice / sex) with no obvious abnormalities in the anterior segment and fundus were randomly divided into 4 groups according to body weight, with 8 mice in each group (4 mice / sex). The vehicle control substance (PBS buffer) and the commercially available control substance ( 40mg / mL), DS032 and DS035 were administered in a volume of 2μL / eye, with the day of administration as D1 ( The day of drug administration was D32. On D29, all animals underwent fundus laser induction of CNV. During the experiment, all animals were clinically observed every day; weighed at the time of receipt, before grouping, D1 (before drug administration), D8, D15, D22, D29 (before modeling), D36 and D43; general ophthalmological examination was performed before grouping, D1 (before drug administration), D29 (before modeling), D36 and D43; fundus photography and angiographic fluorescence angiography were performed before grouping, D29 (immediately after modeling, only fundus photography), D36 and D43.

[0112] (3) Results: In the mouse CNV model experiment, DS032 and DS035 were able to reduce the third-order spot rate and improve fluorescence leakage at the dose of 2E7 GC / eye and 2E9 GC / eye 5 weeks (D36) and 6 weeks (D43) after administration of AAV8 virus carrying DS032. The average spot leakage score at the dose of 2E9 GC / eye 6 weeks after administration was significantly lower than that of the vehicle control group (p≤0.05), and the drug efficacy was more obvious, close to (40 mg / mL, 8 μg / eye). At 5 weeks (D36) and 6 weeks (D43) after administration, the AAV8 virus carrying DS0352 at a dose of 2E7 GC / eye and 2E9 GC / eye could reduce the rate of third-order spot and improve fluorescence leakage. At 6 weeks after administration, the average score of spot leakage at a dose of 2E7 GC / eye was significantly lower than that of the vehicle control group (p≤0.05), and the drug efficacy was more obvious, close to (40 mg / mL, 8 μg / eye). In this experiment, after 36 and 43 days of administration, the two drug sequences, after being packaged and delivered by AAV viral vectors, showed similar effects to the control drug. The similar efficacy results after 3 and 10 days of administration indicate that the drug has a more lasting efficacy. The data are shown in Table 2 and Figure 4 .

[0113] Table 2. Results of drug efficacy studies in AAV8 CNV model mice carrying different drug structural sequences

[0114]

[0115] Note: Values ​​are Mean±SD, *p≤0.05 compared with the vehicle control group during the same period.

[0116] References

[0117] 1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet (London, England). 2018; 392 (10153): 1147-59.

[0118] 2.Ambati J, Fowler BJ. Mechanisms of age-related maculardegeneration. Neuron. 2012; 75(1):26-39.

[0119] 3.Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiatedretinal pigment epithelial cells are immunoreactive for vascular endothelialgrowth factor in surgically excised age-related macular degeneration-relatedchoroidal neovascular membranes. Investigative ophthalmology&visualscience.1996;37(5):855-68.

[0120] 4.Spilsbury K,Garrett KL,Shen WY,Constable IJ,RakoczyPE.Overexpression of vascular endothelial growth factor(VEGF) in the retinal pigment epithelium leads to the development of choroidalneovascularization.2000:157(1):135-44.

[0121] 5.Gil-Martinez M,Santos-Ramos P,Fernandez-Rodriguez M,Abraldes MJ,Rodriguez-Cid MJ,Santiago-Varela M,et al.Pharmacological Advances in theTreatment of Age-related Macular Degeneration.Current medicinalchemistry.2020:27(4):583-98.

[0122] 6.Mones J,Srivastava SK,Jaffe GJ,Tadayoni R,Albini TA,Kaiser PK,et al.Risk of Inflammation,Retinal Vasculitis,and Retinal Occlusion-RelatedEvents with Brolucizumab:Post Hoc Review of HAWK andHARRIER.Ophthalmology.2021:128(7):1050-9.

[0123] 7.Development of the Economics, Emergency Management.Proceedings of the National Institutes of Health.2002(01):55-7.

[0124] 8.Harkins KA,Haschke M,Do DV.Aflibercept for the treatment of diabetic macular edema.Immunotherapy.2016:8(5):503-1

[0125] 9.Shibuya M.VEGF-VEGFR System as a Target for SuppressingInflammation and other Diseases.Endocrine,metabolic&immune disorders drugtargets.2015;15(2):135-44。

Claims

1. An isolated nucleic acid molecule, characterized in that The nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:

7.

2. The nucleic acid molecule according to claim 1, characterized in that The nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:

3.

3. The nucleic acid molecule according to claim 2, characterized in that The nucleic acid molecule also comprises a nucleotide sequence with a signal peptide number as shown in SEQ ID NO:

9.

4. An isolated nucleic acid molecule, characterized in that The nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:

5.

5. The nucleic acid molecule according to claim 4, characterized in that The nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:

1.

6. An isolated nucleic acid molecule, characterized in that The nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:

8.

7. The nucleic acid molecule according to claim 6, characterized in that The nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:

4.

8. The nucleic acid molecule according to claim 7, characterized in that The nucleic acid molecule also comprises a nucleotide sequence with a signal peptide number as shown in SEQ ID NO:

10.

9. An isolated nucleic acid molecule, characterized in that The nucleic acid molecule encodes the amino acid sequence shown in SEQ ID NO:

6.

10. The nucleic acid molecule according to claim 9, characterized in that The nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID NO:

2.

11. A recombinant virus, characterized in that: The recombinant virus comprises the nucleic acid molecule of any one of claims 1-10.

12. The recombinant virus according to claim 11, characterized in that The recombinant virus also includes a combination of the following regulatory elements in the polynucleotide expression cassette: (1) Inverted terminal repeat sequence ITR1 of AAV2 virus (2) CMV promoter (3) CMV enhancer (4) Kozak sequence (5) VEGFR1 signal peptide (6) BGH PloyA sequence.

13. The recombinant virus according to claim 12, characterized in that The virus is an adenovirus-associated virus.

14. The recombinant virus according to claim 13, characterized in that The adenovirus-associated virus is selected from any of the following serotypes: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 or AAV11.

15. The recombinant virus according to claim 14, characterized in that The virus is AAV8.

16. Use of the nucleic acid molecule according to any one of claims 1 to 10 or the recombinant virus according to any one of claims 11 to 14 in the preparation of a medicament for treating or preventing an eye disease associated with VEGF.

17. The use according to claim 16, characterized in that The VEGF-related eye disease is an eye disease of intraocular neovascularization.

18. The use according to claim 16 or 17, characterized in that: The VEGF-associated eye disease is age-related macular degeneration.

19. The use according to claim 18, characterized in that The VEGF-associated eye disease is wet age-related macular degeneration.